Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,00
KB0,00
PKN56,1356,150,86
Msft-1,46
Nokia4,5474,6810,78
IBM-0,43
Mercedes-Benz Group AG56,7656,78-1,11
PFE-0,35
08.02.2025 2:04:00
Indexy online
AD Index online
select
AD Index online
 

  • 07.02.2025 21:59:45
Xenon Pharma (NASDAQ Cons)
Poslední obchod Změna (%) Změna (USD) Objem obchodů (ks)
39,21 -0,98 -0,39 264 894
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 09.02.2025
Popis společnosti
Obecné informace
Název společnostiXenon Pharmaceuticals Inc
TickerXENE
Kmenové akcie:Ordinary Shares
RICXENE.O
ISIN-
Prioritní akciePreference Shares
Poslední známé roční výsledky31.12.2023
Poslední známé čtvrtletní výsledky30.09.2024
Počet zaměstnanců k 31.12.2023 251
Akcie v oběhu k 08.11.2024 76 239 602
MěnaUSD
Kontaktní informace
Ulice3650 Gilmore Way
MěstoVANCOUVER
PSČV5G 4W8
ZeměCanada
Kontatní osoba 
Funkce kontaktní osoby 
Telefon16 044 843 300
Fax16044843450

Business Summary: Xenon Pharmaceuticals Inc. is a Canada-based neuroscience-focused biopharmaceutical company committed to discovering, developing, and commercializing therapeutics to improve the lives of people living with neurological and psychiatric disorders. The Company is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, the Company's lead Kv7 channel opener, represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development for multiple indications. Azetukalner is being developed for the treatment of epilepsy, including focal onset seizures (FOS) and primary generalized tonic-clonic seizures (PGTCS) as well as major depressive disorder (MDD). The Company is evaluating multiple therapeutic candidates targeting Kv7, Nav1.7, and Nav1.1 across various indications. It has an ongoing collaboration with Neurocrine Biosciences, Inc. to develop treatments for epilepsy.
Financial Summary: BRIEF: For the nine months ended 30 September 2024, Xenon Pharmaceuticals Inc revenues was not reported. Net loss increased 23% to $168.6M. Higher net loss reflects Research and development increase of 19% to $150.9M (expense), General and administrative increase of 50% to $50.9M (expense), Unrealized fair value gain on trading se decrease from $3.4M (income) to $0K.
Odvětvová klasifikace
TRBC2012Bio Therapeutic Drugs
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSResearch and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
NAICS2007Pharmaceutical Preparation Mfg
NAICS1997Pharmaceutical Preparation Manufacturing
SICCommercial Physical Research



  • Poslední aktualizace: 09.02.2025
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
President, Chief Executive Officer, DirectorIan Mortimer4803.06.2021
Chief Financial OfficerSherry Aulin4104.06.2021
Executive Vice President - Drug DiscoveryJames Empfield6309.02.2016
Executive Vice President - Strategy and InnovationRobin Sherrington63
Chief Medical OfficerChristopher Kenney53
Chief Legal Officer, Corporate SecretaryAndrea Difabio5507.11.202207.11.2022